Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MAP2K1 F129L |
Therapy | Trametinib |
Indication/Tumor Type | ovarian serous carcinoma |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 F129L | ovarian serous carcinoma | resistant | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, MAP2K1 F129L was identified in a low grade serous ovarian cancer cell line that developed resistance to treatment with Mekinist (trametinib) in culture (PMID: 36198031). | 36198031 |
PubMed Id | Reference Title | Details |
---|---|---|
(36198031) | NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition. | Full reference... |